The Country Manager/Cluster Lead for West Africa at Pfizer, Pharm. Olayinka Subair has emphasized the importance of industry stakeholders coming together to raise awareness about the risks associated with counterfeit medications and pharmaceutical products.
During a visit by Prof. Cyril Usifoh, the President of the Pharmaceutical Society of Nigeria (PSN), to Pfizer’s Nigerian office, Subair stated, “The issue of counterfeit products remains a persistent threat. Pfizer is actively seeking partnerships with stakeholders to educate consumers about the dangers of counterfeit drugs, as patients need the information to safeguard their well-being from fraudulent suppliers.”
Counterfeit medications frequently lack vital components and proper dosages or may contain harmful additives.
Consequently, patients who unknowingly consume counterfeit medicines, including essential treatments for cancer and heart conditions, miss out on the intended therapeutic effects crucial for managing their health.
To address the menace posed by counterfeit drugs, Pfizer is collaborating with various industry partners to ensure that patients know what is necessary to avoid falling victim to counterfeit products.
“Pfizer is dedicated to forging alliances with governmental bodies, pharmaceutical associations, medical professionals, pharmacists, and other industry collaborators to raise awareness about the escalating issue of counterfeit medications.
“Our goal is to confront this threat to patient health by intercepting counterfeit drugs before they reach consumers, providing consumers with informed choices, and offering support to healthcare providers in our communities.”
In response, the President of PSN affirmed, “As an organization committed to upholding stringent professional ethics and standards within its membership, the Pharmaceutical Society of Nigeria is fully committed to partnering with Pfizer. We will explore avenues to amplify our efforts by engaging stakeholders, aiming to drive this campaign effectively.”